Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study

Mariusz Stępień, Anna Stępień, Rafał N Wlazeł, Marek Paradowski, Maciej Banach, Jacek Rysz, Mariusz Stępień, Anna Stępień, Rafał N Wlazeł, Marek Paradowski, Maciej Banach, Jacek Rysz

Abstract

Background: The aim of this study was to estimate associations between inflammatory markers and obesity indices in normo- and hypertensive subjects.

Methods: 65 obese adult subjects were divided into two groups: (A) of hypertensives (n = 54) and (B) of normotensives (n = 11). Waist circumference (WC), body mass index (BMI), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), visceral adiposity index (VAI), body adiposity index (BAI) and tumor necrosis factor-α (TNF-α), interleukin (IL)-6 and high sensitivity C-reactive protein (hsCRP) serum concentrations were estimated.

Results: In group A WHtR was higher (0.69 ± 0.07 vs 0.63 ± 0.06; p < 0.01), hsCRP correlated with BMI and WHtR (r = 0.343; p = 0.011 and r = 0.363; p < 0.01, respectively). BAI correlated with hsCRP in group A and B (r = 0.329; p < 0.05 and r = 0.642; p < 0.05; respectively) and in females and males (r = 0.305; p = 0.05 and r = 0.44; p < 0.05, respectively). In females hsCRP was higher (3.2 ± 2.2 mg/l vs 2.1 ± 1.5 mg/l; p < 0.05). In patients without lipid lowering treatment hsCRP and IL-6 were higher (3.2 ± 1.7 mg/l vs 2.4 ±2.2 mg/l; p = 0.01 and 15.9 ± 7.2 pg/ml vs 13.6 ± 9.9 pg/ml; p < 0.01, respectively).

Conclusions: WHtR is a sensitive index associated with chronic inflammation in obese hypertensive subjects. BAI correlates with hsCRP independently of hypertension and sex. hsCRP is more sensitive marker associated with obesity than IL-6 and TNF-α. Lipid lowering treatment influence chronic inflammation.

References

    1. Bastard JP, Maachi M, Lagathu C. et al.Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Net. 2006;17(1):4–12.
    1. Patel PS, Buras ED, Balasubramanyam A. The role of the immune system in obesity and insulin resistance. J Obesity. 2013. p. 9 pages. ID 616193, .
    1. Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediat Inflamm. 2010. p. 19 pages. article ID 802078, doi:10.1155/2010/802078.
    1. Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol. 2013. p. 11 pages. article ID 678159, .
    1. Fuentes E, Fuentes F, Vilahur G, Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediat Inflamm. 2013. p. 11 pages. article ID 136584, doi:10.1155/2013/136584.
    1. de Oliveira Leal V, Mafra D. Adipokines in obesity. Clin Chim Acta. 2013;419:87–94.
    1. Blüher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Prac Res Clin Endocrinol Metab. 2013;27:163–177. doi: 10.1016/j.beem.2013.02.005.
    1. Han JM, Levings MK. Immune regulation in obesity-associated adipose inflammation. J Immunol. 2013;191:527–532. doi: 10.4049/jimmunol.1301035.
    1. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediat Inflamm. 2010. p. 20 pages. ID 513948; doi:10.1155/2010/513948.
    1. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97. doi: 10.1038/nri2921.
    1. Sell H, Eckel J. Adipose tissue inflammation: novel insight into the role of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care. 2010;13:366–370. doi: 10.1097/MCO.0b013e32833aab7f.
    1. De Heredia FP, Gόmez-Martínez S, Marcos A. Chronic and degenerative diseases. Obesity, inflammation and the immune system. 5th International Immunonutrition Workshop. Proc Nutr Soc. 2012;71:332–338. doi: 10.1017/S0029665112000092.
    1. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314:1–16. doi: 10.1016/j.mce.2009.07.031.
    1. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9:191–200.
    1. Niskanen L, Laaksonen DE, Nyyssönen K. et al.Inflammation, abdominal obesity and smoking as predictors of hypertension. Hypertension. 2004;44:859–865. doi: 10.1161/01.HYP.0000146691.51307.84.
    1. Boos CJ, Lip GYH. Is hypertension an inflammatory process? Curr Pharm Design. 2006;12:1623–1635. doi: 10.2174/138161206776843313.
    1. Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for anti-inflammatory actions. Pharmacother. 2005;25:1213–1229. doi: 10.1592/phco.2005.25.9.1213.
    1. Stępień M, Wlazeł RN, Paradowski M. et al.Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients – pilot study. Arch. 2012;8:431–436.
    1. Stepien M, Stepien A, Wlazel RN. et al.Predictors of insulin resistance in patients with obesity: a pilot study. Angiology. 2014;65(1):22–30. doi: 10.1177/0003319712468291.
    1. Lee CM, Huxley RR, Widma RP, Woodward M. Indices of abdominal obesity are better discrimination of cardiovascular risk factor than BMI: a meta-analysis. J Clin Epidem. 2008;61:646–653. doi: 10.1016/j.jclinepi.2007.08.012.
    1. Amato MC, Giordano C, Galia M. for the AlkaMeSy Study Group et al.Visceral Adiposity Index. A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33:920–922. doi: 10.2337/dc09-1825.
    1. Bergman RN, Stefanovski D, Buchanan TA. et al.A better index of body adiposity. Obesity. 2011;19:1083–1089. doi: 10.1038/oby.2011.38.
    1. Lapice E, Maione S, Patti L. et al.Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care. 2009;32:1734–1736. doi: 10.2337/dc09-0176.
    1. Arbel Y, Birati EY, Shapira I. et al.Comparison of different anthropometric measurements and inflammatory biomarkers. Int J Inflam. 2012;2012:124693. doi:10.1155/2012/124693.
    1. Stępień A, Stępień M, Wlazeł RN. et al.New indices of visceral adiposity and its correlation with hs-CRP in patients with obesity. Clin Exp Med Lett. 2011;52:91–95.
    1. Pannacciulli N, Cajntatore FP, Menenna A. et al.C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes. 2001;25:1416–1420. doi: 10.1038/sj.ijo.0801719.
    1. Lichtash CT, Cui J, Guo X. et al.Body adiposity index versus body mass index and anthropometric traits as correlates of cardiometabolic risk factors. PloS ONE. 2013;8(6):e65954. doi: 10.1371/journal.pone.0065954.
    1. Thung-Wei K, Lu IS, Kuo-Chen L. et al.Associations between body mass index and serum levels of C-reactive protein. S Afr Med J. 2009;99:326–330.
    1. Engeli S, Feldpausch M, Gorzelniak K. et al.Association between adiponectin and mediators of inflammation in obese women. Diabetes. 2003;52:942–947. doi: 10.2337/diabetes.52.4.942.
    1. Stepien M, Stepien A, Banach M, New obesity indices and adipokines in normotensive patients and patients with hypertension. Angiology. 2013. doi:10.1177/000331971348580.
    1. Karastergiou K, Smith SR, Greenberg AS, Fried SK. Sex differences in human adipose tissues – the biology of pear shape. Biol Sex Differ. 2012;3:13. doi: 10.1186/2042-6410-3-13.
    1. White UA, Tchoukalova YD. Sex dimorphism and depot differences in adipose tissue function. Biochim Biophys Acta. 2014;1842(3):377–92. doi: 10.1016/j.bbadis.2013.05.006. .
    1. Park HS, Park JY, Yu R. Relationship of obesity and visceral obesity with serum concentrations of CRP, TNF-α and IL-6. Diab Res Clin Pract. 2005;69:29–35. doi: 10.1016/j.diabres.2004.11.007.
    1. Saijo Y, Kiyota N, Kawasaki Y. et al.Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes, Obesity and Metabolism. 2004;6:249–258. doi: 10.1111/j.1462-8902.2003.0342.x.
    1. Khan R, Haque SF, Quaiser S. The inflammatory markers: C-Reactive Protein and TNF-α predict cardiovascular risk in obese North Indian subjects. Biomed Res. 2011;22:475–480.
    1. Gharipour M, Sadeghi M, Mansourian M. et al.Correlation of circulating inflammatory markers, ghrelin, adiponectin with obesity indices in subjects with metabolic syndrome. Pak J Med Sci. 2013;29:264–268.
    1. Agraval N, Chitrika A, Bhattacharjee J, Jain SK. Correlations of tumor necrosis factor-α and interleukin-6 with anthropometric indices of obesity and parameters of insulin resistance in healthy north Indian population. JIACM. 2011;12:196–204.
    1. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab. 2010;95:829–836. doi: 10.1210/jc.2009-1487.
    1. Chan DC, Watts GF, Barrett HR. et al.Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48:877–883.
    1. Park OY, Kim SH, Ahn YK. et al.Statin reduces C-reactive protein and interleukin-6 in normocholesterolemic patients with acute coronary syndrome. Chonnam Med J. 2008;44:13–16. doi: 10.4068/cmj.2008.44.1.13.
    1. Banach M, Nikfar S, Rahimi R, Bielecka-Dabrowa A, Pencina MJ, Mikhailidis DP, Narkiewicz K, Rysz J, Ray KK, Abdollahi M. Lipid and Blood Pressure Meta-Analysis Collaboration Group. The effects of statins on blood pressure in normotensive or hypertensive subjects–a meta-analysis of randomized controlled trials. Int J Cardiol. 2013;168(3):2816–2824. doi: 10.1016/j.ijcard.2013.03.068.
    1. Stępień M, Stępień A, Wlazeł RN, Paradowski M, Banach M, Rysz M, Rysz J. Obesity indices and adipokines in non-diabetic obese patients with early stages of chronic kidney disease. Med Sci Monit. 2013;19:1063–1072.
    1. Barylski M, Małyszko J, Rysz J, Myśliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci. 2011;7(6):1055–1066.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel